Latham & Watkins Advises on Kestra Medical Technologies’ US$196 Million Financing Round

Latham & Watkins has advised Andera Partners, Ally Bridge Group, Longitude Capital, Omega Funds, and Gilmartin Capital on their investment in Kestra Medical Technologies (Kestra), a privately held wearable medical device and digital healthcare company, in an oversubscribed US$196 million funding round. The funding will support the expansion of Kestra’s commercial organization and advance its mission of protecting at-risk patients with its modern wearable cardioverter defibrillator.

The round was co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds with participation from new investors, funds, and accounts advised by T. Rowe Price Investment Management, Inc., Eventide Asset Management, and Gilmartin Capital. Long-term investors Bain Capital and Endeavour Vision also participated with significant contributions.

The Latham team was led by London corporate partner Robbie McLaren, with associates Matthew O’Connor and Kirill Grishin. Advice on US corporate matters was provided by Boston partner Emily Taylor; and on French tax matters by Paris partner Xavier Renard, with associate Hugo Matricon.